Leerink Swann Equities Analysts Decrease Earnings Estimates for United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) – Stock analysts at Leerink Swann dropped their FY2018 EPS estimates for United Therapeutics Corporation in a note issued to investors on Wednesday, Zacks Investment Research reports. Leerink Swann analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $10.73 for the year, down from their previous estimate of $11.57. Leerink Swann also issued estimates for United Therapeutics Corporation’s FY2019 earnings at $6.79 EPS.

Other equities research analysts also recently issued research reports about the stock. TheStreet downgraded shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a research report on Friday, September 29th. BidaskClub cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, Cowen and Company restated a “hold” rating and set a $129.00 target price on shares of United Therapeutics Corporation in a research note on Friday, October 27th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $132.82.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Equities Analysts Decrease Earnings Estimates for United Therapeutics Corporation (UTHR)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/12/fy2018-eps-estimates-for-united-therapeutics-corporation-uthr-decreased-by-leerink-swann.html.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at $121.00 on Friday. United Therapeutics Corporation has a 1 year low of $112.01 and a 1 year high of $169.89. The stock has a market cap of $5,238.48, a price-to-earnings ratio of 10.69 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The firm had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. During the same quarter in the previous year, the firm posted $4.23 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year.

A number of large investors have recently modified their holdings of UTHR. Wells Fargo & Company MN grew its holdings in United Therapeutics Corporation by 144.0% during the 2nd quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock valued at $94,785,000 after purchasing an additional 431,210 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in United Therapeutics Corporation by 308.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock valued at $64,930,000 after purchasing an additional 378,002 shares during the last quarter. Renaissance Technologies LLC grew its holdings in United Therapeutics Corporation by 65.5% during the 2nd quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock valued at $108,662,000 after purchasing an additional 331,400 shares during the last quarter. Schroder Investment Management Group grew its holdings in United Therapeutics Corporation by 42.8% during the 2nd quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock valued at $143,359,000 after purchasing an additional 327,360 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in United Therapeutics Corporation by 58.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 726,760 shares of the biotechnology company’s stock valued at $94,286,000 after purchasing an additional 266,790 shares during the last quarter.

In other news, Director Christopher Causey sold 580 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $134.48, for a total transaction of $77,998.40. Following the sale, the director now directly owns 3,295 shares in the company, valued at approximately $443,111.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,274 shares of the company’s stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $116.07, for a total transaction of $147,873.18. Following the sale, the chief executive officer now owns 2,343 shares in the company, valued at $271,952.01. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,793 shares of company stock worth $2,081,621. Corporate insiders own 7.80% of the company’s stock.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics Corporation (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply